Merck KGaA makes noise in hematology with $1.1B Silence buy
Silence Therapeutics lead siRNA assetPositive
AI Analysis
Summary
Merck KGaA is buying Silence Therapeutics for $1.1 billion to gain its lead siRNA asset for the rare blood cancer polycythemia vera. The asset has drawn analyst praise in a tight race to challenge Takeda in a potential $2 billion market.
Outcome Details
Merck KGaA to acquire Silence Therapeutics for $1.1B, gaining a lead siRNA asset for polycythemia vera.
Importance:8/10
Sentiment:
0.60
acquisitionM&AsiRNApolycythemia verahematologyrare disease
Related Companies
Read the original article
Published by BioSpace on October 19, 2026 3:17 PM